Skip to main content
Videos

Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Improves Survival in Early-Stage Triple-Negative Breast Cancer

Overall Survival Results From the Phase 3 KEYNOTE-522 Study 


Peter Schmid, MD, PhD, Barts Cancer Institute, London, United Kingdom, discussed overall survival (OS) results from the phase 3 KEYNOTE-522 study which evaluated the addition of neoadjuvant pembrolizumab to chemotherapy followed by adjuvant pembrolizumab for patients with high-risk, early-stage triple-negative breast cancer (TNBC).

The study showed that the addition of pembrolizumab yielded statistically significant and clinically meaningful improvement in OS vs neoadjuvant chemotherapy alone in this patient population.

Dr Schmid presented these results at the 2024 European Society of Medical Oncology (ESMO) Congress in Barcelona, Spain.


Source: 

Schmid P, Cortez J, Dent RA, et al. Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase III KEYNOTE-522 study. Presented at 2024 ESMO Congress. September 13-17, 2024. Abstract LBA4

© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.